Caribou Biosciences (CRBU) Non-Current Deferred Tax Liability (2020 - 2025)

Caribou Biosciences (CRBU) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $4.3 million in Q4 2025.

• Non-Current Deferred Tax Liability for Q4 2025 came in at $4.3 million, down 47.23% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.3 million (down 47.23% YoY), and the FY2025 annual result was $4.3 million, down 47.23% from the prior year.
• Non-Current Deferred Tax Liability advanced to $4.3 million in Q4 2025 per CRBU's latest filing, from $548000.0 in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $9.3 million in Q4 2023 and troughed at $155000.0 in Q2 2021.
• A 5-year average of $1.5 million and a median of $476000.0 in 2021 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2023 and 2025: Non-Current Deferred Tax Liability surged 2345.14% in 2023, then tumbled 47.23% in 2025.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $476000.0 in 2021, then decreased by 19.96% to $381000.0 in 2022, then surged by 2345.14% to $9.3 million in 2023, then dropped by 13.24% to $8.1 million in 2024, then slumped by 47.23% to $4.3 million in 2025.
• Business Quant data shows CRBU's Non-Current Deferred Tax Liability at $4.3 million in Q4 2025, $548000.0 in Q3 2025, and $548000.0 in Q2 2025.